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Abstract: Degradation of mRNA by RNA interference is one of the most powerful and 
specific mechanisms for gene silencing. However, insufficient cellular uptake and poor 
stability have limited its usefulness. Here, we report efficient delivery of siRNA via the use 
of biodegradable nanoparticles (NPs) made from monomethoxypoly(ethylene glycol)-
poly(lactic-co-glycolic acid)-poly-l-lysine (mPEG-PLGA-PLL) triblock copolymers. 
Various physicochemical properties of mPEG-PLGA-PLL NPs, including morphology, 
size, surface charge, siRNA encapsulation efficiency, and in vitro release profile of siRNA 
from NPs, were characterized by scanning electron microscope, particle size and zeta 
potential analyzer, and high performance liquid chromatography. The levels of siRNA 
uptake and targeted gene inhibition were detected in human lung cancer SPC-A1-GFP cells 
stably expressing green fluorescent protein. Examination of the cultured SPC-A1-GFP 
cells with fluorescent microscope and flow cytometry showed NPs loading Cy3-labeled 
siRNA had much higher intracellular siRNA delivery efficiencies than siRNA alone and 
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Lipofectamine-siRNA complexes. The gene silencing efficiency of mPEG-PLGA-PLL 
NPs was higher than that of commercially available transfecting agent Lipofectamine while 
showing no cytotoxicity. Thus, the current study demonstrates that biodegradable NPs of 
mPEG-PLGA-PLL triblock copolymers can be potentially applied as novel non-viral 
vectors for improving siRNA delivery and gene silencing. 
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1. Introduction 
Small interfering RNA (siRNA) is a promising biological strategy for treatment of diverse diseases, 
because of their superior ability to silence target genes in a specific manner. It has been demonstrated 
that siRNA induces sequence-specific degradation of complementary mRNA, leading to knock down 
of a target protein in post-transcriptional level [1,2]. Nevertheless, the use of siRNA in clinical 
applications has been questioned due to several obstacles including poor intracellular uptake and 
severe enzymatic degradation under in vivo circumstances [3,4]. To overcome the limitations, various 
cationic polymers, peptides, and lipids have been extensively utilized to form nanosized polyelectrolyte 
complexes via electrostatic interactions with siRNA [5–7]. These polyelectrolyte complexes could 
protect siRNA from degradation by nucleases and facilitate cellular uptake of siRNA into target cells 
or tissues by an endocytic pathway [8−10]. Nowadays, nanoparticle-mediated delivery of biomolecules 
has attracted much attention of the researchers in areas related to therapeutics. It is also expected that 
due to smaller size, nanoparticles (NPs) will be less susceptible to reticuloendothelial system clearance 
and will have better penetration into tissues and cells, when used for in vivo therapy. However, there 
are still serious problems such as cytotoxicities induced by cationic carriers and stability in the 
presence of serum [11]. Much effort, therefore, has been dedicated to the development of efficient 
carrier materials that are non-toxic, biocompatible and biodegradable. 
Polymeric NPs prepared from biocompatible and biodegradable poly(lactic-co-glycolic acid) 
(PLGA) have been extensively investigated as non-viral gene delivery systems due to their favorable 
physicochemical characteristics in terms of the safety and achieving sustained release [12]. A major 
drawback of PLGA NPs is that they are hydrophobic and have a high negative charge on their surface, 
which limits the interaction with the negatively charged DNA/RNA, in addition to the poor transport 
characteristics of the DNA/RNA encapsulated PLGA NPs through the cell membrane [13]. As a result, 
such a system, when administered in experimental animals, is rapidly opsonized by the defense system 
of the body (Reticuloendothelial System, RES or Mononuclear Phagocyte System, MPS). 
Incorporation of additional excipients such as polyethylene glycol (PEG) used to coat the PLGA NPs 
has been attempted as a method to improve the solubility of the NPs, minimize their aggregation 
caused by hydrophobic surfaces, endow these nanoparticles with ‘stealth’, or RES/MPS evading properties, 
and finally, improve transfection efficiency [14,15]. Previous studies indicate that nanoparticles 
fabricated using PLGA alone result in poor encapsulation of siRNA due to the negative charges on 
their surface [16,17]. The cationic polymer, poly(L-lysine) (PLL) has been widely applied in gene 
delivery vectors. The primary ε-amine groups of lysine in PLL could electrostatically interact with Int. J. Mol. Sci. 2012, 13 518 
 
 
negatively charged DNA or siRNA [18,19] and help to improve the affinity to proteins and cells [20]. 
In addition, due to the large number of active functional groups with amino, PLL could be modified 
with various kinds of ligands to achieve active targeting to tissues and cells [21]. On the basis of  
PEG-PLGA, in order to improve the siRNA loading capacity, here we try to design a biodegradable 
triblock copolymer monomethoxypoly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly-l-lysine 
(mPEG-PLGA-PLL), which combines the physicochemical characteristics of cationic polymer PLL, 
biodegradable polymer PLGA and PEG. 
Based on these considerations, the purpose of the present work was to synthesize the novel 
biodegradable mPEG-PLGA-PLL NPs encapsulating siRNA, and examine the physical properties of 
NPs and in vitro siRNA release profile from NPs. The extent of intracellular siRNA uptake and GFP 
gene silencing effect were evaluated to explore the potential of mPEG-PLGA-PLL NPs as non-viral 
vectors for gene transport.  
2. Results and Discussion  
2.1. Characterization of mPEG-PLGA-PLL Triblock Copolymer 
A novel mPEG-PLGA-PLL triblock copolymer was obtained by acidolysis of mPEG-PLGA-PZLL 
that was synthesized from the ROP of Nε-CBZ-l-lysine NCA with amino-terminated mPEG-PLGA-NH2 
as a macroinitiator. The results measured by the GPC method showed that mPEG-PLGA-PLL triblock 
copolymer had a molecular weight of 11 kDa. 
The basic characteristic of mPEG-PLGA-PLL triblock copolymer involved in the degradation study 
was presented in Figure 1. The final in vitro degradation products of mPEG-PLGA-PLL were oligomers 
of lactic acid, oligomers of glycolic acid, lactic acid, glycolic acid, mPEG and PLL. The degradation of 
mPEG-PLGA-PLL was evaluated by measuring lactate generation with incubation time in PBS   
(pH 7.4). With prolonged incubation time, the rate of lactate formation gradually increased, and 
degradation rate of triblock copolymer approached 80% on 15th day. 
Figure 1. Lactate generation from mPEG-PLGA-PLL with incubation time in   
PBS (pH 7.4). 
 Int. J. Mol. Sci. 2012, 13 519 
 
 
2.2. Physicochemical Characterization of NPs Loading siRNA 
We adapted a w/o/w double emulsion method to fabricate Cy3-siRNA loaded NPs composed of 
mPEG-PLGA-PLL triblock copolymers. Schematic illustration of NPs loading siRNA in PLGA-PLL 
core with mPEG arms was shown in (Figure 2A). The cationic PLL tightly bound siRNA in the inner 
water phase. Furthermore, mPEG-PLGA-PLL NPs formed a rigid structure due to ionic interaction 
between the basic amino groups of amino-terminated mPEG-PLGA and the carboxylic anions of PLL. 
The presence of mPEG chains in the outer shell layer was used to improve the stability and 
biocompatibility of NPs. SEM photograph confirmed that the mPEG-PLGA-PLL NPs had a spherical 
structure (Figure 2B). The mean diameter of blank NPs was 140  62 nm and the zeta potential was 
+11.4 mV. The size of NPs binding siRNA was 151  74 nm (Figure 2C), whereas zeta potential of 
NPs loading siRNA was found to decrease to −0.13 mV (Figure 2D). HPLC was used to determine the 
Cy3-siRNA encapsulation efficiency in NPs and the release profile of Cy3-siRNA from NPs in vitro. 
The encapsulation efficiency of siRNA in mPEG-PLGA-PLL NPs was 86.06%. Figure 3 showed the 
release profile of siRNA from NPs in PBS (pH 7.4) at 37 °C. Biodegradable NPs prepared from 
mPEG-PLGA-PLL triblock copolymers sustained the longer-lasting siRNA release over 10 days after 
the initial burst of 20–30%. 
Figure 2. Characterization of NPs loading siRNA. (A) Schematic illustration of NPs 
loading Cy3-siRNA in PLGA-PLL core with mPEG arms; (B) SEM photograph of   
mPEG-PLGA-PLL NPs containing Cy3-siRNA; (C, D) Size distribution and zeta potential 
of NPs loading siRNA measured with a particle size and zeta potential analyzer. 
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Figure 3. In vitro release profile of siRNA from NPs. 
 
2.3. Gel Retardation Assay 
The preparation of mPEG-PLGA-PLL/siRNA nanocomplexes could lead to the electro-neutralization 
of the negative charge of siRNA, which were unable to migrate under the influence of electric field 
during gel electrophoresis. To confirm the formation of the triblock copolymer/siRNA nanocomplexes 
by the combination of mPEG-PLGA-PLL with siRNA, a gel retardation assay was performed in this 
study. As shown in Figure 4, complete binding of siRNA with the mPEG-PLGA-PLL (without the 
presence of a free siRNA band) could be observed when the weight ratio of the triblock copolymer/siRNA 
was at 600:1, which was consistent with our preparation method of NPs loaded with siRNA. 
Furthermore, the retardation of migration was more obvious when the triblock copolymer/siRNA 
weight ratio was increased. However, when the weight ratio of the triblock copolymer/siRNA was at 
300:1, a weak free siRNA band in lane 3 could be observed, indicating insufficient complexation of 
siRNA with copolymer. 
Figure 4. Gel retardation assay of mPEG-PLGA-PLL/siRNA nanocomplexes. Lane 1, a 21 bp 
siRNA marker; lane 2, siRNA alone; lane 3, the triblock copolymer/siRNA weight ratio of 
300:1; lane 4, a weight ratio of 600:1; lane 5, a weight ratio of 900:1. 
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2.4. Celluar Uptake and Location of NPs Loading siRNA 
We compared the cellular uptake efficiencies of siRNA alone, Lipofectamine-siRNA complexes or 
NPs loading siRNA. In order to visualize the uptake, siRNA was fluorescently labeled with Cy3 
conjugated at the 5' end. After 12 h of incubation, examination of the cultured SPC-A1-GFP cells with 
fluorescent microscope showed NPs loading siRNA had much higher intracellular siRNA delivery 
efficiencies than siRNA alone and Lipofectamine-siRNA (Figure 5A). Quantitative cellular uptake of 
Cy3-labeled siRNA was estimated using a FACSCalibur flow cytometer, which further confirmed the 
result observed by fluorescent microscope (Figure 5B and 5C). The maximal siRNA uptake efficiency 
was obtained in the NPs group, which was significantly higher than that of the Lipofectamine-siRNA 
group (92.17 ± 2.54% vs. 74.63 ± 3.84%). However, there was only a small amount of uptake detected 
in  cells treated with siRNA alone. Examination of mean fluorescent intensity of the cultured   
SPC-A1-GFP cells with flow cytometry showed a similar trend to the percentage of Cy3-siRNA 
positive cells in the same treatment group. We clearly noticed intracellular localization of the siRNAs 
was in the perinuclear cytoplasmic region (Figure 5A), and the accumulation of granular NPs loading 
siRNA was also seen in the perinuclear cytoplasm (Figure 6). 
Figure 5. Intracellular uptake of siRNA. (A) Fluorescent images of cellular uptake of 
siRNA in the control and different treatment groups. Red, Cy3-labeled siRNA; blue, nuclei 
stained with Hoechst 33258. Scale  bars represent 20  μm;  (B) Quantitative analysis of 
cellular uptake of siRNA using FACSCalibur; (C)  The flow cytometric picture of  
control cells (a, red) and SPC-A1-GFP cells treated with siRNA alone (b, green),   
Lipofectamine-siRNA (c, blue) or NPs loading siRNA (d, purple) were shown. 
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Figure 6. Localization of intracellular NPs loading Cy3-labeled siRNA. SPC-A1-GFP cells 
were treated with NPs loading Cy3-labeled siRNA and observed at 1000× magnification by 
a confocal microscope for (A) green fluorescence; (B) Cy3 red fluorescence; or (C) blue 
fluorescence of nuclei stained with Hoechst 33258; (D) A merged image of (A), (B) and (C) 
was shown. Scale bars represent 10 μm. 
 
2.5. In Vitro Gene Silencing 
Gene knockdown efficiency of mPEG-PLGA-PLL NPs loading siRNA was estimated by carrying 
out transfections in stable GFP expressing SPC-A1 cells and compared to the commercially available 
transfection reagent, Lipofectamine™ 2000. The efficacy of NPs for gene silencing was determined by 
using FACS measurement and RT-PCR analysis. The qualitative analysis of level of gene silencing 
was carried out by observing under an inverted microscope after 48 h of transfection. The fluorescence 
microscopy images showed that the treatment with NPs loading siRNA effectively suppressed the 
expression of GFP in the cells, compared to other samples (Figure 7).  
Figure 7. Fluorescent microphotos of SPC-A1-GFP cells treated with various siRNA 
formulations after 48 h of transfection. (A) The green fluorescent protein expression was 
observed under fluorescent microscope; (B) Merged images of the green fluorescent 
protein and cells seen under light microscope were shown. Scale bars represent 50 μm. 
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Quantitative analysis of GFP silencing efficiency of various siRNA formulations was measured by 
using a FACSCalibur flow cytometer. The relative level of GFP expression in cells treated with siRNA 
transfection was standardized by setting GFP expression rate and mean fluorescent intensity of control 
cells to 100% (Figure 8A).  After 48 h of transfection, mPEG-PLGA-PLL NPs showed 33.71% 
inhibition of gene expression, which was higher than that for Lipofectamine-siRNA (25.42% 
inhibition). There was statistical difference between the two groups (P = 0.004). Examination of mean 
fluorescence intensity of the cultured SPC-A1-GFP cells with flow cytometry demonstrated the green 
fluorescence signal was decreased by 45.31% when cells treated with NPs loading siRNA while that 
for Lipofectamine-siRNA was 34.49% (P = 0.007). Both GFP expression rate and fluorescent intensity 
of cells treated with siRNA alone showed no difference as compared to control cells (P > 0.05). 
Figure 8. Comparison of gene silencing efficiency of various siRNA formulations after  
48 h of transfection. (A) The level of GFP expression was estimated by the flow cytometric 
quantitation of green fluorescence; (B) RT-PCR analysis for relative GFP mRNA level was 
shown. (** P < 0.01 vs. control group, 
▲▲ P < 0.01 vs. Lipofectamine-siRNA group). 
 
To further establish the gene knockdown efficiency at the mRNA level, a RT-PCR analysis of  
SPC-A1-GFP cells was carried out. The results showed that NPs loading anti-GFP siRNA had a great 
inhibitory effect to GFP gene expression than the other samples (Figure 8B). The inhibition effect of 
siRNA-loaded nanoparticles in SPC-A1-GFP cells was 56.33% while that for Lipofectamine-siRNA 
was 43.72% (P = 0.006). However, naked siRNA revealed negligible silencing effect. 
2.6. Cell Viability Assay 
To estimate the extent of toxicity caused by various siRNA formulations, MTT colorimetric assay 
was performed 48 h after transfection (Figure 9). SPC-A1-GFP cells were treated with various siRNA 
formulations as described in transfection and gene silencing experiment. The treatment of cells with 
mPEG-PLGA-PLL NPs loading siRNA did not induce obvious cell toxicity. However, cell viability 
decreased to 86.39 ± 2.84% after 48 h of Lipofectamine-siRNA treatment, which was significantly 
lower than those of the NPs group and the control group (P = 0.018 and P = 0.001, respectively). 
These results further confirmed that mPEG-PLGA-PLL NPs loading siRNA had the advantage with 
lower toxicity than Lipofectamine™ 2000. Int. J. Mol. Sci. 2012, 13 524 
 
 
Figure 9. Cell viability assay. SPC-A1-GFP cells were treated with various siRNA 
formulations under the transfection conditions. The assays were done in triplicate and   
the standard error was shown. (** P < 0.01 vs. control group, 
▲ P < 0.05 vs. Lipofectamine-
siRNA group). 
 
2.7. Discussion 
Small interfering RNA has been widely investigated as a potential therapeutic for treatment of 
various diseases. However, the use of siRNA is limited due to its rapid degradation and insufficient 
cellular uptake in vitro and in vivo. Despite the high transduction efficiency of viral vectors which are 
derived from viruses by the use of recombinant DNA techniques, their clinical potential should be 
fully understood in terms of issues related to production, safety and immune response that need to be 
addressed [22]. The non-viral vectors have recently gained increasing attention due to their stability, 
safety, ease of preparation, and are easily manufactured for large-scale production for treatment of 
numerous acquired or inherited human diseases [23,24]. Generally, nonviral vectors include liposomes, 
cationic polymers, and nanoparticles. Even though liposomes have been developed that are capable of 
delivering DNA or RNA through the cellular membrane, and achieving high activity of the RNA 
interference, they have shown a relatively low encapsulation efficiency of siRNA molecules, poor 
storage stability, and rapid clearance from the blood [25,26]. The formation of complexes from 
cationic polymers with anionic DNA or oligonucleotide solutions was applied by many research 
groups [27–29]. The simplicity of these self-assembling polyelectrolyte complexes is both an 
advantage and a drawback. Although such complexes are easy to generate and can protect DNA from 
enzymatic degradation, they are always characterized by a broad size distribution and variable   
shape [29], and most of these cationic polymers are not readily biodegradable, which induces high 
toxicity and necrosis [30–32].  
Biodegradable polymeric NPs based on PLGA have been widely investigated as carriers for DNA 
and oligonucleotides due to their small particle size, favorable safety profile and sustained-release 
characteristics [33]. With regards to formulation development, it is very challenging to efficiently 
encapsulate high amounts of hydrophilic macromolecular compounds like siRNA into uniform,   
nano-sized PLGA particles, mainly due to the hydrophobic nature of the PLGA and the absence of 
electrostatic interactions between siRNA and PLGA [34]. In our present study, a novel triblock 
copolymer mPEG-PLGA-PLL was obtained by acidolysis of mPEG-PLGA-PZLL that was Int. J. Mol. Sci. 2012, 13 525 
 
 
synthesized from the ROP of Nε-CBZ-l-lysine NCA with amino-terminated mPEG-PLGA-NH2 as a 
macroinitiator. The triblock copolymers mPEG-PLGA-PLL could combine the characters of cationic 
polymer PLL, biodegradable polymer PLGA and PEG: siRNA-loaded NPs fabricated using triblock 
copolymers possessed a PEG loop structure to increase the stability and biocompatibility, hydrophobic 
PLGA segments as the core, and the primary ε-amine groups of lysine in PLL to electrostatically 
interact with negatively charged phosphate groups of siRNA to deposit with the PLGA core. As a 
result, siRNA was incorporated into the mPEG-PLGA-PLL NPs with an encapsulation efficiency as 
high as 86.06%, which was significantly higher compared to 57% encapsulation efficiency reported in 
the previous study using PLGA NPs for siRNA delivery [34]. Zeta potential measurement provides 
vital information about the surface charge present on the nanoparticles which is measured in the 
presence and absence of siRNA at physiological pH. In this study, zeta potential of the blank mPEG-
PLGA-PLL NPs decreased from +11.4 to −0.33 mV when the siRNA was encapsulated in the core of 
NPs, which might be due to the neutralization effect of the negative charge of siRNA on the positive 
charge of the pure copolymers. Perhaps, the decrease in zeta potential was also partly attributed to 
some negatively charged siRNA adsorbed onto the NPs surface. The particle size of NPs loaded with 
siRNA increased because the siRNA molecules were encapsulated in the inner water phase of   
mPEG-PLGA-PLL NPs. 
The degradation time of PLGA can be altered from days to years by varying the molecular weight, 
the lactic acid to glycolic acid ratio in copolymer, or the structure of nanospheres. In our study, 
biodegradable NPs fabricated using mPEG-PLGA-PLL triblock copolymers showed a longer-lasting 
sustained siRNA release. This finding represents an important advantage for future in vivo applications 
of mPEG-PLGA-PLL NPs-based gene delivery systems. 
Our results demonstrated that mPEG-PLGA-PLL NPs had much higher intracellular siRNA 
delivery efficiencies than siRNA alone and Lipo2000-siRNA complexes. The significantly enhanced 
delivery of the siRNA by mPEG-PLGA-PLL NPs might be due to the presence of PLL and mPEG or 
the small size of NPs. PLL is one of the most used cationic polymers for gene delivery [35], and 
positively charged amine groups of PLL could make electrostatic interactions with negatively charged 
phosphate groups of the nucleic acids. Therefore, we speculate that the PLL may enhance the 
encapsulation efficiency and stability of NPs because they tightly bind siRNA in the inner water phase. 
The presence of a neutral and hydrophilic mPEG shell layer could also effectively enhance gene 
delivery by promoting the biocompatibility of NPs [36]. A previous study showed that NPs that are 
100–200 nm in size offer the best properties for cellular uptake [37]. Therefore, the small size of NPs 
in our present study makes them more suitable for enhanced siRNA delivery via the endocytotic 
pathway. The silencing efficiency measured by a FACSCalibur flow cytometry and quantitative   
real-time RT-PCR showed that mPEG-PLGA-PLL NPs loading siRNA efficiently suppressed GFP 
expression within the lung cancer cells as compared with Lipofectamine, which was consistent with 
the high cellular uptake of NPs loading siRNA. 
Lipofectamine was the most commonly used and commercially available cationic lipid transfection 
agent. However, the results of our study showed that Lipofectamine treatment resulted in only 25% 
inhibition at the protein expression level. The reasons why Lipofectamine-siRNA complexes produced 
only a slight inhibition of GFP were as follows: in our study, lung cancer SPC-A1-GFP cell line stably 
expressing GFP was used for analysis of gene silencing. This type of cell line was obtained through Int. J. Mol. Sci. 2012, 13 526 
 
 
infection with the virus bearing the GFP sequence. SPC-A1-GFP cell line showed a very strong GFP 
expression, therefore, it was very difficult for the Lipofectamine-siRNA complexes to efficiently 
inhibit GFP expression. Nimesh et al. [5] reported that gene silencing efficiency of lipofectamine-siRNA 
complexes was higher in their studies. We found that the cells used in their studies were co-transfected 
with GFP plasmid and GFP-siRNA using Lipofectamine according to manufacturer’s protocol. No 
GFP accumulation existed in the cells treated by this method. However, it was completely different 
from the transfection method used in our study (SPC-A1-cells was firstly transfected with virus 
bearing the GFP sequence, and then was transfected again with lipofectamine-siRNA complexes).  
To further establish the gene knockdown efficiency at the mRNA level, a RT-PCR analysis of  
SPC-A1-GFP cells was also carried out in our study. The results showed that the inhibition effect of 
Lipofectamine-siRNA in SPC-A1-GFP cells was 43.72%, indicating that Lipofectamine treatment was 
efficient. Whereas even though lipofectamine treatment could efficiently knock down the GFP gene 
expression at the mRNA level, a certain amount of GFP accumulation still existed in SPC-A1-GFP 
cells. Therefore, after 48 h of transfection, Lipofectamine treatment resulted in only 25% inhibition at 
the protein expression level. 
Low cytotoxicity and high gene transfection efficiency are critical issues in designing current   
non-viral siRNA delivery vectors. One of the major advantages of mPEG-PLGA-PLL NPs is that the 
siRNA is delivered to the cells without hampering the metabolic activity of cells as revealed by the 
results of MTT assay. The mPEG-PLGA-PLL NPs appear to be a safe gene carrier as evident from 
their low cytotoxicity.  
3. Experimental Section  
3.1. Materials 
Monomethoxypoly(ethylene glycol) (mPEG) with a molecular weight of 2 kDa was obtained from 
Aldrich. L-lactide and glycolide were purchased from Beijing Yuanshengrong Company (Beijing, 
China). Nε-carbobenzyloxy-L-lysine N-carboxyanhydride (Nε-CBZ-L-lysine NCA) was purchased 
from Shanghai Yuanju Biotechnology Company (Shanghai, China).  
The active anti-GFP siRNA was synthesized by Ruibo Biotechnology Company (Guangzhou, 
China) and Cy3 conjugated at the 5' end. The sense and antisense sequences were as follows: 5'- GCU 
GAC CCU GAA GUU CAU CUG dTdT -3' and 5'- CAG AUG AAC UUC AGG GUC AGC dTdT -3', 
respectively. In siRNA transfection and gene silencing experiments, Lipofectamine™ 2000 (Invitrogen) 
was used as a positive control according to the manufacturer’s protocol.  
3.2. Preparation of mPEG -PLGA-PLL NPs Loading siRNA  
The mPEG-PLGA-PLL triblock copolymers was synthesized in four steps as shown in Scheme 1: 
(1) to prepare diblock copolymer mPEG-PLGA-OH by ROP (ring-opening polymerization) of   
L-lactide and glycolide in the presence of mPEG with stannous octanoate as catalyst; (2) to convert its 
end-group -OH into -NH2, i.e., to prepare mPEG-PLGA-NH2. The experimental details were described 
by Deng et al. [38]; (3) to carry out ROP of Nε-CBZ-l-lysine NCA in the presence of mPEG-PLGA-NH2 
as macroinitiator. Purified mPEG-PLGA-PZLL was obtained under vacuum at 40 °C for 24 h; and  Int. J. Mol. Sci. 2012, 13 527 
 
 
(4) the final mPEG-PLGA-PLL triblock copolymers were synthesized by deprotecting the copolymer 
mPEG-PLGA-PZLL in HBr/HAc solution. 
Scheme 1. Synthesis of mPEG-PLGA-PLL triblock copolymers. 
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Gel permeation chromatography (GPC) measurement was conducted on a Waters 410 GPC with 
tetrahydrofuran as eluent (flow rate: 1 mL/min, at 35 °C). The molecular weight of mPEG-PLGA-PLL 
triblock copolymer was calibrated against polystyrene standards. 
The degradation behavior of mPEG-PLGA-PLL triblock copolymer was evaluated by the lactate 
generation. The determination method used in the present study was the same as that used previously 
to determine the lactate [39]. mPEG-PLGA-PLL samples (1 mL), enclosed in dialysis bags (cellulose 
membrane, mw cut-off 5 kDa, Sigma-Aldrich, Co., St. Louis, MO, USA), were incubated in 30 mL 
phosphate buffer saline (PBS, pH 7.4) at 37 °C under mild agitation in a water bath. For lactate assay, 
500 μL samples were withdrawn from the incubation medium at predetermined time intervals. The 
samples were replaced by equal volume of fresh PBS. The lactate formed during mPEG-PLGA-PLL 
hydrolysis was determined by an enzymatic method based on the quantitative oxidation of lactate to 
pyruvate in the presence of lactate dehydrogenase (Lactate diagnostic Kit 826, Sigma). The samples 
were first saponified with an equal volume of a 0.1 M NaOH solution for 30 min at room temperature 
to hydrolyze lactic acid oligomers that form in solution and thus evade determination. After Int. J. Mol. Sci. 2012, 13 528 
 
 
neutralization with a 0.1 M HCl solution, the L-lactate concentration was measured using the 
enzymatic assay. The absorbance of the samples was measured at 340 nm. 
We prepared mPEG-PLGA-PLL NPs containing siRNA using a w/o/w double emulsion method. 
Briefly, 50 μL of DEPC-treated water (W1) containing 13.3 μg of siRNA were emulsified with 400 μL 
of CH2Cl2 (O) containing 8 mg of mPEG-PLGA-PLL with an ultrasonic processor (400 W 10 × 10 s) 
(JY92-II ultrasonic processor, Ningbo Scientz Biotechnology Co., Ltd., Ningbo, China). Then, the 
resulting W1/O emulsion was poured into 4.4 mL of DEPC-treated water with 1% Pluronic F-68 (W2), 
and the mixture was homogenized by ultrasound (400 W 10 × 10 s). The resulting W1/O/W2 emulsion 
was stirred gently at room temperature for 3 h to evaporate the organic solvent. The NPs were passed 
through a 0.45-μm sieved to remove large particles and then sedimented by centrifugation at 14000 
rpm for 30 min. The mPEG-PLGA-PLL NPs containing siRNA were collected by centrifugation, 
rinsed with distilled water three times, and then lyophilized. 
3.3. Physicochemical Characterization of NPs Loading siRNA 
NPs were observed using an S-4800 field emission scanning electron microscope (SEM) (Hitachi, 
Tokyo, Japan). The samples were coated with 25-nm-thick gold using a quick carbon coater (SC-701, 
Sanyu Electronics, Tokyo, Japan). The NPs containing siRNA were collected by centrifugation, rinsed 
with distilled water three times to remove free siRNA, and then suspended in 0.1 M PBS (pH 7.4). The 
diameter and zeta potential of the final NPs in 0.1 M PBS (pH 7.4) were measured by the Nicomp 380 
ZLS Particle Size and Zeta Potential Analyzer (PSS Nicomp, Santa Barbara, CA, USA). 
The siRNA encapsulation efficiency in NPs was determined by high performance liquid 
chromatography (HPLC). The method used in the present study was the same as that used previously 
to measure the siRNA encapsulation efficiency [40]. In brief, NPs (4 mg) were dissolved in 0.1 mL of 
acetonitrile, and then 0.4 mL of phosphate buffer (pH 6.0) was added. After vigorous shaking for 2 h, 
the supernatants collected by centrifugation (14000 rpm, 30 min) were analyzed using a model 1200 
series HPLC (Agilent Technologies, Santa Clara, CA USA) with an ultraviolet (UV) detector as 
follows: a 4.6 mmФ × 30 cm TSK-Gel SuperSW3000 column (Tosoh Biosciences, Inc. Stuttgart, 
Germany); mobile phases, (A) 0.1 M triethylamine-acetic acid solution, (B) acetonitrile; flow rate, 1.0 
mL/min; wave length, 260 nm; injection volume, 20 μL. The ratio (%) of the measured, to the 
formulated amount of siRNA was defined as the encapsulation efficiency of siRNA in NPs. 
In the in vitro release experiment, NPs (20 mg) were suspended in 2.0 mL of 0.1 M phosphate 
buffer (pH 7.4), and stirred with a rotator at 37 °C. The NPs and supernatants were periodically 
collected by centrifugation at 14,000 rpm for 30 min. The amount of residual siRNA in NPs was 
determined using the same analytical method of encapsulation efficiency. The amount of released 
siRNA was also determined by HPLC. The released siRNA (%) from NPs was calculated as a ratio (%) 
of the released amount, to the total amount of detected siRNA (µg). 
3.4. Gel Retardation Assay 
The binding of siRNA with mPEG-PLGA-PLL was determined by 4% agarose (low melting point) 
gel electrophoresis. Three different weight ratios of mPEG-PLGA-PLL/siRNA nanocomplexes were 
loaded (20 μL of the sample containing 0.2 μg of siRNA). A 1:6 dilution of loading dye was added to Int. J. Mol. Sci. 2012, 13 529 
 
 
each well and electrophoresis was carried out at a constant voltage of 55 V, for 1 h in TBE buffer  
(4.45 mM Tris–base, 1 mM sodium EDTA, 4.45 mM boric acid, pH 8.3) containing 0.5 μg/mL 
ethidium bromide. The siRNA bands were then visualized under a UV transilluminator at a wavelength 
of 365 nm. 
3.5. Cell Culture 
Human lung cancer SPC-A1 cell line and SPC-A1-GFP cell line stably expressing green fluorescent 
protein were kindly donated by Cancer Institute of Renji Hospital Affiliated to Shanghai Jiaotong 
University School of Medicine (Shanghai, China). Both cell lines were cultivated in Dulbecco’s 
modified Eagle’s medium (DMEM) (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine 
serum (FBS) at 37 °C and 5% CO2 atmosphere.  
3.6. Celluar Uptake Studies 
SPC-A1-GFP cells were seeded in 24-well plates at a density of 1 × 10
5 cells per well, and 
incubated in 500 μL DMEM with 10% FBS for 24 h. Then, the medium was removed by aspiration, 
and the cells were washed twice with phosphate buffered saline. Lipofectamine-siRNA complexes 
were prepared as follows: First, dilute 15 μL siRNA in 35 μL of FBS-free DMEM. Mix gently and 
incubate for 5 minutes at room temperature. Second, dilute 2 μL Lipofectamine™ 2000 in 48 μL of 
FBS-free DMEM. Mix gently and incubate for 5 minutes at room temperature. Last, after the 5-minute 
incubation, combine the diluted siRNA with the diluted Lipofectamine™ 2000. Mix gently and 
incubate for 20 minutes at room temperature to allow complex formation to occur. siRNA alone, 
Lipofectamine-siRNA complexes or nanoparticles loading siRNA (equivalent with 0.8 μg siRNA each 
well) and a certain amount of FBS-free DMEM (siRNA alone group: 485 μL, Lipofectamine-siRNA 
complexes group: 400 μL, siRNA-loaded nanoparticles group: 310 μL) were added to the 24-well 
plates ensuring that the final volume per well was 500 µL. After 12 h of culture, the transfection 
medium was removed and the cells were washed three times with phosphate buffer saline. Then, the 
cells were fixed at room temperature for 15 min with 4% paraformaldehyde, washed with PBS and 
mounted with Slow Fade® reagent (Moleculer probes Inc., Eugene, OR, USA) containing the nuclear 
stain Hoechst 33258 (Dojindo Lab., Kumamoto, Japan). Intracellular siRNA uptake and localization 
were imaged using an Olympus IX-51 fluorescence microscopy (Olympus Optical Company, Ltd., 
Tokyo, Japan; exposure time: 0.5 seconds and camera aperture: 0.3) and a confocal laser scanning 
microscopy (LSM 510 META, Carl Zeiss Inc., Jena, Germany) equipped with argon (488 nm) and 
HeNe (543 nm) lasers. Intracellular fluorescence was determined using a fluorescence-activated cell 
sorter (FACS) Calibur flow cytometer (Becton Dickinson, CA, USA) and the data were analyzed by 
Win MDI softwares. All experiments were carried out in triplicate. 
3.7. Analysis of Gene Silencing 
SPC-A1 and SPC-A1-GFP lung cancer cells were seeded in 24-well plates at a density of 1 × 10
5 
cells per well, and incubated in 500 μL DMEM with 10% FBS for 24 h. SPC-A1 lung cancer cells that 
were not treated with siRNA were used as a negative control. siRNA alone, Lipofectamine-siRNA Int. J. Mol. Sci. 2012, 13 530 
 
 
complexes or nanoparticles loading siRNA (equivalent with 0.8 μg siRNA each well) was added to 
stable GFP expressing SPC-A1 cell cultures and a certain amount of FBS-free DMEM (siRNA alone 
group: 485 μL, Lipofectamine-siRNA complexes group: 400 μL, siRNA-loaded nanoparticles group: 
310 μL) was also added to the 24-well plates ensuring that the final volume per well was 500 µL. After 
12 h of incubation, the transfection medium was replaced with 500 µL of fresh culture media 
containing 10% FBS and the cells were incubated at 37 °C for 48 h in a humidified 5% CO2 
atmosphere. The efficiency of GFP silencing was visualized under an Olympus IX-51 fluorescence 
microscope (exposure time: 0.05 seconds and camera aperture: 0.3) and measured by FACS analysis. 
After 48 h of transfection, inhibition of the GFP gene mRNA expression was also evaluated by 
using quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). SPC-A1-GFP 
cells were treated with various siRNA formulations as above-described in transfection and gene 
silencing experiments. The cells were harvested, lysed, and total RNA was extracted from respective 
samples using Trizol Reagent Kit (Invitrogen, Karlsruhe, Germany), according to the manufacturer's 
protocol. Additionally, SPC-A1-GFP cells that were not treated with siRNA were used as a control, 
and also collected to measure the mRNA levels. Then, reverse transcription to synthesize cDNA was 
achieved using First Strand cDNA Synthesis Kit (GeneCopoeia Inc, Rockville, MD, USA). RT-PCR 
was performed with the extracted total RNA by using SYBR® Premix Ex Taq™ 
 (Perfect. Real Time) 
kit (TaKaTa, Tokyo, Japan). The PCR primers used to detect GFP were: (forward) 5′- 
TGGCGATGGCCCTGTCCTTT -3′; (reverse) 5′- TGCCATGTGTAATCCCAGCAGCT -3′. 
Quantification, using the 2
−ΔΔCT analytical method, was performed in triplicate with GAPDH as the 
internal standardization. 
3.8. Cytotoxicity 
The cell viability in the different treatment groups and control group was evaluated by MTT method. 
SPC-A1-GFP cells were seeded onto 96-well plates at a density of 1 × 10
4 cells/well and incubated for 
24 h to allow for cell adherence. The cells were treated as described in the transfection experiment 
with siRNA alone, Lipofectamine-siRNA complexes or nanoparticles loading siRNA. After 48 h of 
transfection, 20 µL  of 5 mg/mL MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
solution was added to each well, and cells was incubated for 4 h at 37 °C. Then, the MTT containing 
medium was aspirated, and the formazan crystals formed by the living cells were dissolved in 150 µL 
DMSO. The absorbance was measured spectrophotometrically in an ELISA plate reader at 570 nm. 
Untreated cells were taken as control with 100% viability and cells without the addition of MTT were 
used as blank to calibrate the spectrophotometer to zero absorbance. The relative cell viability (%) 
compared to control cells was calculated by [abs]sample/[abs]control × 100. 
3.9. Statistical Analysis 
Data were expressed as the means and standard deviation (mean ± SD). Independent samples t-test 
was used to determine the significance of the difference between two groups. Analysis of variance 
(ANOVA) was used to test for significance by multiple comparisons. Differences were considered 
significant at P < 0.05. Statistical analyses were performed with a software package (SPSS, version 
13.0; SPSS, Chicago, IL, USA). Int. J. Mol. Sci. 2012, 13 531 
 
 
4. Conclusions  
In conclusion, development of safe and efficient non-viral vectors has received tremendous 
attention in the hope of finding a substitute for viral vectors. The novel biodegradable   
mPEG-PLGA-PLL NPs could successfully transfer siRNA into lung cancer cells, and produced higher 
gene inhibition efficiency than commercially available transfecting agent Lipofectamine, while 
showing no cytotoxicity. The results of this study suggest that biodegradable NPs of   
mPEG-PLGA-PLL triblock copolymers can be potentially applied as novel non-viral vectors for 
improving siRNA delivery and gene silencing. Our future study will focus on the surface-modification 
of mPEG-PLGA-PLL triblock copolymers with various kinds of ligands to achieve active targeting to 
tissues and cells, thereby building the “perfect vector” for systemic gene therapy against cancer. 
Acknowledgments 
The work was supported by the National Natural Science Foundation of China (No. 30772369), 
National 973 Basic Research Program of China (No.2010CB529902) and Nano-Science and Technology 
from Science and Technology Commission of Shanghai Municipality (No.1052nm 05900). 
Conflicts of Interest  
The authors declare no conflicts of interests related to this manuscript. 
References  
1.  Dorsett, Y.; Tuschl, T. siRNAs: Applications in functional genomics and potential as therapeutics. 
Nat. Rev. Drug Discov. 2004, 3, 318–329.  
2.  Novina, C.D.; Sharp, P.A. The RNAi revolution. Nature 2004, 430, 161–164. 
3.  Dykxhoorn, D.M.; Lieberman, J. The silent revolution: RNA interference as basic biology, 
research tool, and therapeutic. Annu. Rev. Med. 2005, 56, 401–423. 
4.  Ryther, R.C.; Flynt, A.S.; Phillips, J.A.; Patton, J.G. siRNA therapeutics: Big potential from small 
RNAs. Gene Ther. 2005, 12, 5–11. 
5.  Nimesh, S.; Chandra, R. Polyethylenimine nanoparticles as an efficient in vitro siRNA delivery 
system. Eur. J. Pharm. Biopharm. 2009, 73, 43–49. 
6.  Crombez, L.; Charnet, A.; Morris, M.C.; Aldrian-Herrada, G.; Heitz, F.; Divita, G. A   
non-covalent peptide-based strategy for siRNA delivery. Biochem. Soc. Trans. 2007, 35, 44–46.  
7.  Hatakeyama, H.; Akita, H.; Ito, E.; Hayashi, Y.; Oishi, M.; Nagasaki, Y.; Danev, R.; Nagayama, K.; 
Kaji, N.; Kikuchi, H.; et al. Systemic delivery of siRNA to tumors using a lipid nanoparticle 
containing a tumor-specific cleavable PEG-lipid. Biomaterials 2011, 32, 4306–4316. 
8.  Schiffelers, R.M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P.Y.; Scaria, 
P.V.; Woodle, M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted 
sterically stabilized nanoparticle. Nucleic Acids Res. 2004, 32, e149.  
9.  Hassani, Z.; Lemkine, G.F.; Erbacher, P.; Palmier, K.; Alfama, G.; Giovannangeli, C.; Behr, J.P.; 
Demeneix, B.A. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in 
the mouse brain at picomolar levels. J. Gene Med. 2005, 7, 198–207. Int. J. Mol. Sci. 2012, 13 532 
 
 
10.  Park, T.G.; Jeong, J.H.; Kim, S.W. Current status of polymeric gene delivery systems. Adv. Drug 
Deliv. Rev. 2006, 58, 467–486. 
11.  Lee, S.H.; Bae, K.H.; Kim, S.H.; Lee, K.R.; Park, T.G. Amine-functionalized gold nanoparticles 
as non-cytotoxic and efficient intracellular siRNA delivery carriers. Int. J. Pharm. 2008, 364, 94–101. 
12.  Prabha, S.; Zhou, W.Z.; Panyam, J.; Labhasetwar, V. Size-dependency of nanoparticle-mediated 
gene transfection: studies with fractionated nanoparticles. Int. J. Pharm. 2002, 244, 105–115. 
13.  Nafee, N.; Taetz, S.; Schneider, M.; Schaefer, U.F.; Lehr, C.M. Chitosan-coated PLGA 
nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and 
transfection of antisense oligonucleotides. Nanomedicine 2007, 3, 173–183. 
14.  Vij, N.; Min, T.; Marasigan, R.; Belcher, C.N.; Mazur, S.; Ding, H.; Yong, K.T.; Roy, I. 
Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in 
cystic fibrosis. J. Nanobiotechnol. 2010, 8, 22. 
15.  Prabha, S.; Labhasetwar, V. Critical determinants in PLGA/PLA nanoparticle-mediated gene 
expression. Pharm. Res. 2004, 21, 354–364. 
16.  Patil, Y.; Panyam, J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int.  J. 
Pharm. 2009, 367, 195–203. 
17.  Tahara, K.; Yamamoto, H.; Hirashima, N.; Kawashima, Y. Chitosan-modified poly(D,L-lactide-
co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur.  J. 
Pharm. Biopharm. 2010, 74, 421–426. 
18.  Sun, X.; Zhang, N. Cationic polymer optimization for efficient gene delivery. Mini Rev. Med. 
Chem. 2010, 10, 108–125. 
19.  Patil, M.L.; Zhang, M.; Minko, T. Multifunctional triblock Nanocarrier (PAMAM-PEG-PLL) for 
the efficient intracellular siRNA delivery and gene silencing. ACS Nano 2011, 5, 1877–1887. 
20.  Deng, C.; Chen, X.S.; Yu, H.J.; Sun, J.; Lu, T.C.; Jing, X.B. A biodegradable triblock copolymer 
poly(ethylene glycol)-b-poly(l-lactide)-b-poly(l-lysine): Synthesis, self-assembly, and RGD 
peptide modification. Polymer 2007, 48, 139–149. 
21.  Fu, C.; Sun, X.L.; Liu, D.H.; Chen, Z.J.; Lu, Z.J.; Zhang, N. Biodegradable tri-block copolymer 
Poly(lactic acid)-poly(ethylene glycol)-poly(L-lysine)(PLA-PEG-PLL) as a non-viral vector to 
enhance gene transfection lower gene transfection efficiency. Int. J. Mol. Sci. 2011, 12, 1371–1388. 
22.  Wolff, J.A.; Rozema, D.B. Breaking the bonds: non-viral vectors become chemically dynamic. 
Mol. Ther. 2008, 16, 8–15. 
23.  Niven, R.; Zhang, Y.; Smith, J. Toward development of a non-viral gene therapeutic. Adv. Drug 
Deliv. Rev. 1997, 26, 135–150. 
24.  Pişkin, E.; Dinçer, S.; Türk, M. Gene delivery: Intelligent but just at the beginning. J. Biomater. 
Sci. Polym. Ed. 2004, 15, 1181–1202. 
25.  Zhang, C.; Tang, N.; Liu, X.; Liang, W.; Xu, W.; Torchilin, V.P. siRNA-containing liposomes 
modified with polyarginine effectively silence the targeted gene. J. Control. Release 2006, 112, 
229–239. 
26.  Ishida, T.; Harada, M.; Wang, X.Y.; Ichihara, M.; Irimura, K.; Kiwada, H. Accelerated blood 
clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and 
PEG surface-density and chain length of the first-dose liposomes. J. Control. Release 2005, 105, 
305–317. Int. J. Mol. Sci. 2012, 13 533 
 
 
27.  Kim, T.H.; Kim, S.I.; Akaike, T.; Cho, C.S. Synergistic effect of poly(ethylenimine) on the 
transfection efficiency of galactosylated chitosan/DNA complexes. J. Control. Release 2005, 105, 
354–366. 
28.  Park, M.R.; Han, K.O.; Han, I.K.; Cho, M.H.; Nah, J.W.; Choi, Y.J.; Cho, C.S. Degradable 
polyethylenimine-alt-poly(ethylene glycol) copolymers as novel gene carriers. J. Control. Release 
2005, 105, 367–380. 
29.  Köping-Höggård, M.; Vårum, K.M.; Issa, M.; Danielsen, S.; Christensen, B.E.; Stokke, B.T.; 
Artursson, P. Improved chitosan-mediated gene delivery based on easily dissociated chitosan 
polyplexes of highly defined chitosan oligomers. Gene Ther. 2004, 11, 1441–1452. 
30.  Itaka, K.; Ishii, T.; Hasegawa, Y.; Kataoka, K. Biodegradable polyamino acid-based polycations as 
safe and effective gene carrier minimizing cumulative toxicity. Biomaterials 2010, 31, 3707–3714.  
31.  Jere, D.; Jiang, H.L.; Arote, R.; Kim, Y.K.; Choi, Y.J.; Cho, M.H.; Akaike, T.; Cho, C.S. 
Degradable polyethylenimines as DNA and small interfering RNA carriers. Expert Opin. Drug 
Deliv. 2009, 6, 827–834.  
32.  Nounou, M.I.; Emmanouil, K.; Chung, S.; Pham, T.; Lu, Z.; Bikram, M. Novel reducible linear  
L-lysine-modified copolymers as efficient nonviral vectors. J. Control Release 2010, 143, 326–334. 
33.  Luten, J.; van Nostrum, C.F.; De Smedt, S.C.; Hennink, W.E. Biodegradable polymers as   
non-viral carriers for plasmid DNA delivery. J. Control. Release 2008, 126, 97–110. 
34.  Cun, D.; Foged, C.; Yang, M.; Frøkjaer, S.; Nielsen, H.M. Preparation and characterization of 
poly(dl-lactide-co-glycolide) nanoparticles for siRNA delivery. Int. J. Pharm. 2010, 390, 70–75. 
35.  Morille, M.; Passirani, C.; Vonarbourg, A.; Clavreul, A.; Benoit, J.P. Progress in developing cationic 
vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008, 29, 3477–3496.  
36.  Zhang, M.Z.; Kataoka, K. Nano-structured composites based on calcium phosphate for cellular 
delivery of therapeutic and diagnostic agents. Nano Today 2009, 4, 508–517 
37.  Qi, X.L.; Chen, X.Y.; Sun, Y.; Ma, Z.C.; Guo, X.J.; Lu, W.; Duan, Y.R. Cytotoxicity and cellular 
uptake evaluation of mitoxantrone-loaded poly (lactic acid-co-lysine) arginine–glycine–aspartic 
acid nanoparticles. J. Appl. Polym. Sci. 2011, 119, 1011–1015.  
38.  Deng, C.; Tian, H.; Zhang, P.; Sun, J.; Chen, X.; Jing, X. Synthesis and characterization   
of poly(ethylene glycol)-b-poly (L-lactide)-b-poly(L-glutamic acid) triblock copolymer. 
Biomacromolecules 2006, 7, 590–596. 
39.  Avgoustakis, K.; Beletsi, A.; Panagi, Z.; Klepetsanis, P.; Karydas, A.G.; Ithakissios, D.S. PLGA-
mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in 
vivo drug residence in blood properties. J. Control. Release 2002, 79, 123–135. 
40.  Murata, N.; Takashima, Y.; Toyoshima, K.; Yamamoto, M.; Okada, H. Anti-tumor effects of  
anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Control. Release 2008, 126, 
246–254. 
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 